Whitehawk Therapeutics, Inc. — Director's Dealing 2017

Mar 17, 2017

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Aerpio Pharmaceuticals, Inc. (NONE)
CIK: 0001422142
Period of Report: 2017-03-15

Reporting Person: Satter Muneer A (Director, 10% Owner)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2017-03-15	Common Stock	P	1120000	$5.00	Acquired	3241835	Indirect

Footnotes

F1: Represents shares acquired by Satter Medical Technology Partners, L.P. in a private placement offering by the Company that occurred immediately following the merger of a wholly-owned subsidiary of the Company with and into Aerpio Therapeutics, Inc.

F2: The amount in Column 5 includes (a) 980,124 shares that are held by the Muneer A. Satter Revocable Trust for which the Reporting Person serves as trustee and, in such capacity, has sole voting and dispositive power over all such shares, (b) 1,141,711 shares that are held by various other trusts and other entities for which the Reporting Person serves as trustee, investment advisor or manager and, in such capacity, has sole voting and dispositive power over all such shares, and (c) 1,120,000 shares that are held by Satter Medical Technology Partners, L.P. for which the Reporting Person has sole voting and dispositive power over all such shares. The Reporting Person disclaims beneficial ownership of all shares included in clauses (b) and (c) of this footnote (2), except to the extent of his pecuniary interest.